Navigation Links
Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
Date:12/3/2010

MYSTIC, Conn. and DUBLIN, Dec. 3, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) today announced that it is scheduled to present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference on Tuesday, December 7, 2010 at 3:00pm PST. The conference will be held at the Nikko Hotel in San Francisco.

A live audio webcast of the presentation will be available at the following URL:  

http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3331020

About AmarinAmarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate).On November 29, 2010, the Company reported positive, statistically significant top-line results from the MARINE trial, the first of its Phase 3 clinical trials of AMR101. In the MARINE trial, AMR101 was investigated as a treatment for very high triglycerides(>500 mg/dL). AMR101 is presently being investigated in a second Phase 3 clinical trial, the ANCHOR trial, for the treatment of patients on statin therapy with high triglycerides (≥200 and <500mg/dL) with mixed dyslipidemia. The MARINE trial was, and the ANCHOR trial currently is, conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information, including a summary of MARINE trial top-line results, please visit www.amarincorp.com.Investor Contact Information: John F. Thero President In U.S.: +1 (860) 572-4979 investor.relations@amarincorp.comLee M. Stern The Trout Group In U.S.: +1 (646) 378-2922 lstern@troutgroup.comMedia Contact Information: David Schull or Martina Schwarzkopf, Ph.D.Russo Partners In U.S.: +1 (212) 845-4271 or +1 (212) 845-4292 (office) +1 (347) 591-8785 (mobile) david.schull@russopartnersllc.commartina.schwarzkopf@russopartnersllc.comMark Swallow or David Dible CitigateDeweRogersonIn U.K.: +44 (0)207 638 9571 mark.swallow@citigatedr.co.uk
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
2. Amarin to Present at UBS Life Sciences Conference
3. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
4. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
5. InfraReDx to Present at Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference
6. VIVUS to Present at Two Upcoming Investor Conferences
7. Dendreon Announces Presentation of PROVENGE Data at the American Society of Hematology and the Society of Urologic Oncology Annual Meetings
8. HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference
9. Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
10. Masimo to Present at Piper Jaffray 22nd Annual Healthcare Conference
11. Beckman Coulter to Present at the Piper Jaffray 22nd Annual Unplugged Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 /PRNewswire/ ... ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron Ehlen ... the signing of a three-year exclusive sales representation ... a dedicated sales team to introduce Imprimis, ophthalmic ... focused in 13 states in the U.S. Midwest. Precision ...
(Date:4/18/2017)... 18, 2017 Research and Markets has ... States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023" ... ... equipment revenues as well as growth in the number of ... value to market participants that design and manufacture molecular imaging ...
(Date:4/18/2017)... 2017 Recursion Pharmaceuticals , an emerging ... learning techniques to discover treatments for rare genetic diseases, ... as vice president of biology. Chong joins the ... Belgium , where as a principal ... high-dimensional biological approaches to the small molecule lead discovery ...
Breaking Medicine Technology:
(Date:4/23/2017)... , ... April 23, 2017 , ... ... managed services announced the achievement of Cisco Select certification and SMB specialization. ... United States. , In earning the Select Certification, Altura fulfilled the ...
(Date:4/22/2017)... Juan Capistrano (PRWEB) , ... April 22, 2017 , ... The San Juan Capistrano ... recently released a parenting report outlining the need for summer camps to provide physical activities ... The Importance of Physical Activity In Summer Camps , With an increase in specialty camps ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. Shah, ... is a benign bony lump located on the forehead usually attributed to a facial ... sight and pain. Dr. Shah has discovered an approach that is minimally invasive. He ...
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” applies perfectly ... in the company’s esteemed VISION House demonstration project series. Manifesting the concept of right-sized ... resources they need to live affordably and abundantly without unduly taxing the resources of ...
(Date:4/21/2017)... ... 2017 , ... The American Medical Student Association (AMSA) will ... Education, from April 24 to April 28, 2017, dedicated to increasing awareness about ... mission of AWARE is to instill a compassionate, total health approach to treating ...
Breaking Medicine News(10 mins):